BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 23578317)

  • 21. [Clinical efficacy of a standardized specific immunotherapy against house dust mite in 85 asthmatic children].
    Zhang X; Li MR; Wang C; Wang XN; Zhang HL; Lin J; Jin K; Li YC
    Zhonghua Er Ke Za Zhi; 2010 Jul; 48(7):526-30. PubMed ID: 21055090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vitamin D as an adjunct to subcutaneous allergen immunotherapy in asthmatic children sensitized to house dust mite.
    Baris S; Kiykim A; Ozen A; Tulunay A; Karakoc-Aydiner E; Barlan IB
    Allergy; 2014 Feb; 69(2):246-53. PubMed ID: 24180595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Depigmented and polymerised house dust mite allergoid: allergen content, induction of IgG4 and clinical response.
    Gallego MT; Iraola V; Himly M; Robinson DS; Badiola C; García-Robaina JC; Briza P; Carnés J
    Int Arch Allergy Immunol; 2010; 153(1):61-9. PubMed ID: 20357486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes.
    Keles S; Karakoc-Aydiner E; Ozen A; Izgi AG; Tevetoglu A; Akkoc T; Bahceciler NN; Barlan I
    J Allergy Clin Immunol; 2011 Oct; 128(4):808-815.e7. PubMed ID: 21641635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing subcutaneous and sublingual immunotherapy.
    Yukselen A; Kendirli SG; Yilmaz M; Altintas DU; Karakoc GB
    Asian Pac J Allergy Immunol; 2013 Sep; 31(3):233-41. PubMed ID: 24053706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significant improvement of specific bronchial hyperreactivity in asthmatic children after 4 months of treatment with a modified extract of dermatophagoides pteronyssinus.
    Ibero M; Castillo MJ
    J Investig Allergol Clin Immunol; 2006; 16(3):194-202. PubMed ID: 16784014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapeutic efficacy of 3-year subcutaneous immunotherapy in asthmatic children allergic to mite].
    Li L; Hui Y; Qian J; Guo Y; Zhang XL; Zhang XJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 May; 15(5):368-71. PubMed ID: 23676940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of a cluster specific immunotherapy in children with bronchial asthma and mite allergy.
    Schubert R; Eickmeier O; Garn H; Baer PC; Mueller T; Schulze J; Rose MA; Rosewich M; Renz H; Zielen S
    Int Arch Allergy Immunol; 2009; 148(3):251-60. PubMed ID: 18849616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of bronchial and nasal allergen provocation in children and adolescents with bronchial asthma and house dust mite sensitization.
    Fischl A; Eckrich J; Passlack V; Klenke SK; Hartmann D; Herrmann E; Schulze J; Zielen S
    Pediatr Allergy Immunol; 2020 Feb; 31(2):143-149. PubMed ID: 31660641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two year follow-up of immunological response in mite-allergic children treated with sublingual immunotherapy. Comparison with subcutaneous administration.
    Antúnez C; Mayorga C; Corzo JL; Jurado A; Torres MJ
    Pediatr Allergy Immunol; 2008 May; 19(3):210-8. PubMed ID: 18399897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum-specific IgE and allergen immunotherapy in allergic children.
    Tosca M; Silvestri M; Accogli A; Rossi GA; Ciprandi G
    Immunotherapy; 2014; 6(1):29-33. PubMed ID: 24341881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subcutaneous Immunotherapy for Allergic Asthma in a Single Center of Korea: Efficacy, Safety, and Clinical Response Predictors.
    Lee JH; Kim SC; Choi H; Jung CG; Ban GY; Shin YS; Nahm DH; Park HS; Ye YM
    J Korean Med Sci; 2017 Jul; 32(7):1124-1130. PubMed ID: 28581269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different Responses in Induction of Allergen Specific Immunoglobulin G4 and IgE-Blocking Factors for Three Mite Subcutaneous Immunotherapy Products.
    Park KH; Lee SC; Son YW; Jeong KY; Shin YS; Shin JU; Sim da W; Park HJ; Lee JH; Lee KH; Park JW
    Yonsei Med J; 2016 Nov; 57(6):1427-34. PubMed ID: 27593871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bronchial allergen challenges in children - safety and predictors.
    Schulze J; Reinmüller W; Herrmann E; Rosewich M; Rose MA; Zielen S
    Pediatr Allergy Immunol; 2013 Feb; 24(1):19-27. PubMed ID: 23331526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subcutaneous immunotherapy with purified Der p1 and 2 suppresses type 2 immunity in a murine asthma model.
    Hesse L; van Ieperen N; Habraken C; Petersen AH; Korn S; Smilda T; Goedewaagen B; Ruiters MH; van der Graaf AC; Nawijn MC
    Allergy; 2018 Apr; 73(4):862-874. PubMed ID: 29318623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma.
    Agache I; Lau S; Akdis CA; Smolinska S; Bonini M; Cavkaytar O; Flood B; Gajdanowicz P; Izuhara K; Kalayci O; Mosges R; Palomares O; Papadopoulos NG; Sokolowska M; Angier E; Fernandez-Rivas M; Pajno G; Pfaar O; Roberts GC; Ryan D; Sturm GJ; van Ree R; Varga EM; van Wijk RG; Yepes-Nuñez JJ; Jutel M
    Allergy; 2019 May; 74(5):855-873. PubMed ID: 31095767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective comparison of a nonmodified and a modified mite extract for immunotherapy in children and adolescents.
    Hartmann D; Fischl A; Herrmann E; Schulze J; Schubert R; Zielen S
    Immunotherapy; 2019 Aug; 11(12):1015-1029. PubMed ID: 31319714
    [No Abstract]   [Full Text] [Related]  

  • 38. Functional and Immunoreactive Levels of IgG4 Correlate with Clinical Responses during the Maintenance Phase of House Dust Mite Immunotherapy.
    Feng M; Su Q; Lai X; Xian M; Shi X; Wurtzen PA; Qin R; Zeng X; Li J
    J Immunol; 2018 Jun; 200(12):3897-3904. PubMed ID: 29728509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Allergen-specific immune therapy in the treatment of asthma].
    Malling HJ
    Ugeskr Laeger; 2000 Jan; 162(4):477-9. PubMed ID: 10697443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma.
    Ameal A; Vega-Chicote JM; Fernández S; Miranda A; Carmona MJ; Rondón MC; Reina E; García-González JJ
    Allergy; 2005 Sep; 60(9):1178-83. PubMed ID: 16076305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.